The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. This is particularly important when the recommended agent is a new and/or infrequently employed drug.ĭisclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. There is no associated inflammation and the central cornea is of normal thickness. Distribution permitted for non-commercial purposes only.ĭrug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. A 35 year-old male patient with pellucid marginal corneal degeneration underwent crescentic lamellar excision with autolamellar dissection on his left eye. PMD is uncommon and is characterized by a crescent-shaped band of inferior corneal thinning approaching 20 of normal thickness that is 1 to 2 mm in height, 6 to 8 mm in horizontal extent, and 1 to 2 mm from the limbus.
(Pellucid Marginal Degeneration progresses for much. Materials and Methods: Literature review via PubMed. Stabilise the progression of the disease Typically keratoconus progresses until you are in your mid 30s. Pellucid marginal degeneration (PMD) of the cornea is a progressive, rare, and uncommon noninflammatory corneal disorder characterized by the thinning in the peripheral portion of the inferior cornea with marked steepening just superior to the thinned zone.
#Pellucid marginal degeneration treatment license
Open Access License: This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) ( applicable to the online version of the article only. Purpose: To describe the clinical features of Pellucid Marginal Degeneration (PMD) and to give an overview of current treatment options. Corneal collagen cross-linking is especially exciting because it halts disease progression. Intacs implants, corneal collagen cross-linking, and corneal transplant surgery are additional options. Treatment usually consists of vision correction with eyeglasses or contact lenses. Corneal pachymetry may be useful in confirming the diagnosis. Open Access License / Drug Dosage / Disclaimer Current options in the management of pellucid marginal degeneration Although little is understood about the etiology, pathophysiology, epidemiology, and genetics of PMD, new treatments are improving visual outcomes and reducing complications. Pellucid marginal degeneration is diagnosed by corneal topography.
0 kommentar(er)
